Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis

Internal Medicine

Volumn 41, Issue 12, 2002, Pages 1118-1123

  Nagai, Sonoko ^a   Hamada, Kunio ^a   Shigematsu, Michio ^a   Taniyama, Masayosi ^b   Yamauchi, Shitotomo ^b   Izumi, Takateru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Aircraft Maintenance Business Div   (Japan)

Author keywords

Adverse effects; Idiopathic pulmonary fibrosis; Interstitial pneumonia associated with systemic sclerosis; Therapeutic effects; Usual interstitial pneumonia

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; OXYGEN; PIRFENIDONE; PREDNISOLONE;

ADULT; AGED; ALLERGIC REACTION; ANOREXIA; ARTERIAL OXYGEN TENSION; ARTICLE; BODY WEIGHT; BRONCHOPNEUMONIA; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FORCED EXPIRATORY VOLUME; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LIVER DISEASE; LUNG FIBROSIS; LUNG FUNCTION; MALAISE; MALE; PATIENT CARE; PHOTOSENSITIVITY; SCORING SYSTEM; SHOCK; SOMNOLENCE; SURVIVAL; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

EID: 0036967820     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.1118     Document Type: Article

References (23)

1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157: 1301-1315, 1998.
2. Nagai S, M. Kitaichi, T. Izumi. Classification and recent advances in idiopathic interstitial pneumonia. Curr Opin in Pul Med 4: 256-260, 1998.
3. Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 24: 19-33, 2000.
4. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157: 199-203, 1998.
5. Nagai S, Kitaichi M, Nishimura K, Itoh H, Izumi T, Colby TV. Idiopathic Nonspecific Interstitial Pneumonia/Fibrosis: Comparison with Idiopathic Pulmonary Fibrosis and Bronchiolitis Obliterans Organizing Pneumonia. Eur Respir J 12: 1010-1019, 1998.
6. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of non-specific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 160: 899-905, 1999.
7. American Thoracic Society, European Respiratory Society. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonia. Am J Respir Crit Care Med 165: 277-304, 2002.
8. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 151: 915-918, 1995.
9. King Jr. TE, Costabel U, Cordier JF, et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med 161: 646-664, 2000.
10. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells A. The prognostic significance of the histopathologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162: 2213-2217, 2000.
11. Katzenstein ALA. Systemic diseases involving the lung. in: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 3rd Ed., WB Saunders, Philadelphia, 1997: 168-192.
12. Silver RM. Interstitial lung diseases of systemic sclerosis. Int Rev Immunol 12: 281-291, 1995.
13. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 149: 1583-1590, 1994.
14. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis: Past, present, and future. Am J Respir Crit Care Med 160: 1771-1777, 1999.
15. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144: 291-296, 1991.
16. Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 155: 395-420, 1997.
17. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Eng J Med 341: 1264-1269, 1999.
18. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 159: 1061-1069, 1999.
19. Raghu G. Idiopathic pulmonary fibrosis: A need for treatment with drugs other than corticosteroids-a role for antifibrotic agents? Mayo Clin Proc 72: 285-287, 1997.
20. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 52: 77-78, 1997.
21. Watters LC, Talmadge EK, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 133: 97-103, 1986.
22. JMP statistical software for the Macintosh. Carry NC., SAS Institute, 1994.
23. Dawson-Saunders B, Trapp RG. Basic and clinical biostatitstics. 2nd ed. Prentice-Hall International, London, 1994: 189-209.